JP2023526517A - 運動失調症を治療するためのアセチルロイシンと４－アミノピリジン又はアセタゾラミドとの組合せ - Google Patents

運動失調症を治療するためのアセチルロイシンと４－アミノピリジン又はアセタゾラミドとの組合せ Download PDF

Info

Publication number
JP2023526517A
JP2023526517A JP2022571228A JP2022571228A JP2023526517A JP 2023526517 A JP2023526517 A JP 2023526517A JP 2022571228 A JP2022571228 A JP 2022571228A JP 2022571228 A JP2022571228 A JP 2022571228A JP 2023526517 A JP2023526517 A JP 2023526517A
Authority
JP
Japan
Prior art keywords
leucine
acetyl
acetazolamide
administered
ataxia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022571228A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526517A5 (https=
Inventor
ストルップ マイケル
Original Assignee
イントラビオ エルティーディー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イントラビオ エルティーディー filed Critical イントラビオ エルティーディー
Publication of JP2023526517A publication Critical patent/JP2023526517A/ja
Publication of JP2023526517A5 publication Critical patent/JP2023526517A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022571228A 2020-05-22 2021-05-20 運動失調症を治療するためのアセチルロイシンと４－アミノピリジン又はアセタゾラミドとの組合せ Pending JP2023526517A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063028760P 2020-05-22 2020-05-22
US63/028,760 2020-05-22
PCT/IB2021/054399 WO2021234642A1 (en) 2020-05-22 2021-05-20 The combination of acetyl leucine and 4-aminopyridine or acetazolamide for treating ataxia

Publications (2)

Publication Number Publication Date
JP2023526517A true JP2023526517A (ja) 2023-06-21
JP2023526517A5 JP2023526517A5 (https=) 2024-05-29

Family

ID=76181172

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571228A Pending JP2023526517A (ja) 2020-05-22 2021-05-20 運動失調症を治療するためのアセチルロイシンと４－アミノピリジン又はアセタゾラミドとの組合せ

Country Status (7)

Country Link
US (1) US20230201150A1 (https=)
EP (1) EP4153161A1 (https=)
JP (1) JP2023526517A (https=)
KR (1) KR20230015433A (https=)
CA (1) CA3179105A1 (https=)
MX (1) MX2022014466A (https=)
WO (1) WO2021234642A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886986A1 (en) * 2018-12-06 2021-10-06 IntraBio Ltd Deuterated analogs of acetyl-leucine
WO2025264957A2 (en) * 2024-06-20 2025-12-26 Intrabio Inc. Acetyl leucine for treating neurodevelopmental disorders

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009269856A (ja) * 2008-05-07 2009-11-19 Nobufumi Ono 異常行動防止薬及びこれを含むインフルエンザ治療薬
JP2010503658A (ja) * 2006-09-13 2010-02-04 ピエール、ファーブル、メディカマン アセチル−ｌ−ロイシンによるめまいの治療
JP2014503596A (ja) * 2011-01-28 2014-02-13 アコーダ セラピューティクス，インコーポレーテッド 脳性麻痺を治療するためのカリウムチャネル遮断薬の使用
JP2019524679A (ja) * 2016-06-27 2019-09-05 ラオフ・レキク サルブタモール含有眼科用医薬
JP2019524822A (ja) * 2016-08-11 2019-09-05 イントラバイオ リミティド 神経変性疾患のための治療薬
WO2020052620A1 (en) * 2018-09-13 2020-03-19 Syneurx International (Taiwan) Corp. Salts of cycloserine compounds and applications thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2588130T (lt) 2010-06-25 2016-12-12 Shire Human Genetic Therapies, Inc. Terapinės priemonės pristatymas cns
WO2021048431A1 (en) * 2019-09-12 2021-03-18 Amabiotics Compounds for treating ataxia

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010503658A (ja) * 2006-09-13 2010-02-04 ピエール、ファーブル、メディカマン アセチル−ｌ−ロイシンによるめまいの治療
JP2009269856A (ja) * 2008-05-07 2009-11-19 Nobufumi Ono 異常行動防止薬及びこれを含むインフルエンザ治療薬
JP2014503596A (ja) * 2011-01-28 2014-02-13 アコーダ セラピューティクス，インコーポレーテッド 脳性麻痺を治療するためのカリウムチャネル遮断薬の使用
JP2019524679A (ja) * 2016-06-27 2019-09-05 ラオフ・レキク サルブタモール含有眼科用医薬
JP2019524822A (ja) * 2016-08-11 2019-09-05 イントラバイオ リミティド 神経変性疾患のための治療薬
WO2020052620A1 (en) * 2018-09-13 2020-03-19 Syneurx International (Taiwan) Corp. Salts of cycloserine compounds and applications thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CEREBELLUM & ATAXIAS, vol. 3:8, JPN6025023572, 2016, ISSN: 0005759926 *
CEREBELLUM, vol. 15:38-42, JPN6025023573, 2016, ISSN: 0005759927 *

Also Published As

Publication number Publication date
US20230201150A1 (en) 2023-06-29
WO2021234642A1 (en) 2021-11-25
MX2022014466A (es) 2022-12-13
CA3179105A1 (en) 2021-11-25
EP4153161A1 (en) 2023-03-29
KR20230015433A (ko) 2023-01-31

Similar Documents

Publication Publication Date Title
JP7329965B2 (ja) Ｓ１ｐ受容体アゴニストの投与レジメン
ES2395462T3 (es) Inhibidores selectivos de la recaptación de norepinefrina-serotonina para el tratamiento del síndrome de fibromialgia, síndrome de fatiga crónica y dolor
JP7737367B2 (ja) α１Ａ－ＡＲ部分アゴニストを用いて神経障害を治療するための方法
US7462595B2 (en) Methods for treating cancer-related fatigue
US20100286188A1 (en) Means for improving cognitive functions and memory based on hydrogenated pyrido(4,3-b)indoles (variants), pharmacological means based thereon and method for the use thereof
EP3056200B1 (en) Huperzine for use in treating seizure
WO2011107583A1 (en) Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
HUE024558T2 (hu) Biotin alkalmazása szklerózis multiplex kezelésére
KR20220054724A (ko) 근위축성 측색경화증의 치료 또는 병세 진전 억제를 위한 약제
JP2023526517A (ja) 運動失調症を治療するためのアセチルロイシンと４－アミノピリジン又はアセタゾラミドとの組合せ
CN110662537A (zh) 用于治疗共核蛋白病的组合物和方法
EP1401424B1 (en) Carbamate compounds for use in preventing or treating psychotic disorders
US20240197756A1 (en) Methods of treatment with neuroactive steroids
EP3490546A1 (en) Methods of treating or preventing amyloid related imaging abnormalities associated with alzheimer's disease treatment
KR102693607B1 (ko) 하지 불안 증후군을 치료하기 위한 치료제
Chen A COMPARATIVE STUDY OF EPHEDRINE, PSEUDO-EPHEDRINE AND ß-PHENYL-ETHYLAMINE: WITH REFERENCE TO THEIR EFFECTS ON THE PUPIL AND ON THE BLOOD PRESSURE
US20250288591A1 (en) Trimeprazine for use in treating trigeminal neuralgia and for reducing pain related thereto
US20230000796A1 (en) Intranasal administration of ketamine to cluster headache patients
CN110325214A (zh) 用于预防和治疗神经元损伤的低剂量药物组合
US20090176857A1 (en) Use of Organic Compounds
US11364218B2 (en) Method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome
US20200281928A1 (en) Vitamin b1 in high doses for use in the medical treatment of motor symptoms of some sporadic neurodegenerative diseases, of genetic origin, and of cluster headache and of migraine headache
JP6126134B2 (ja) 線維筋痛症および慢性疲労症候群の治療のための、（１ｒ，４ｒ）−６’−フルオロ−（Ｎ−メチル−またはＮ，Ｎ−ジメチル−）−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミン
US12502371B2 (en) Drug for treating and preventing dementia
JP2017088584A (ja) 医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240517

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250916

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20251203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260323